All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma hub is happy to present a visual abstract representing key data from a phase 1 trial (NCT02500407) evaluating the safety, efficacy and recommended phase 2 dose for Mosunetuzumab, a bispecific antibody for relapsed or refractory B-cell non-Hodgkin lymphomas. Preliminary results were previously reported in January 2020.
To download this visual abstract, click below.Download here
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Preliminary results from phase I studies of CD20 × CD3 bispecific antibodies in R/R B-cell non-Hodgkin lymphoma
For patients with B-cell non-Hodgkin lymphoma (NHL) who relapse or become refractory to chemotherapy and anti-CD20 immunotherapy, there...
The potential role of liquid biopsy in NHL and its current limitations
Following 15ICML in Lugano, CH, Associate Professor Dipti Talaulikar discusses the potential role of liquid biopsy in non-Hodgkin lymphoma.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox